Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And our portfolio was incredibly relevant, powerful and supportive of the needs of the pandemic, but it also is positioned so well with the changes that I just talked about in our portfolio transformation for the future |
| And when you bring that all together, I think you end up where we are today, which I don't believe is dissimilar from the general view, which is the second half of '23 was better than the first half |
| Certainly, in our business, we had and have an excellent innovation cycle |
| That's really what drives our earnings power, and we believe to create a lot of sustainable value |
| But we believe and have been saying for some time that that's a sustainable low double-digit growth rate, again, faster than the market because of the advantages of the technology for clinicians |
| We've spent a lot of time and energy and build process around being able to improve our visibility, helping our customers also to improve their own visibility to ensure that we're able to anticipate supply chain disruptions and the short and long-term impact that, that might have on the business |
| And so we're seeing share gains through the consolidation on desktops and countertops in the hospital setting from competitive onto the GeneXpert has one modality of growth |
| And we've been making great progress with that |
| So all of that together really has positioned our portfolio into highly attractive end markets with strong secular growth drivers |
| Additionally, it's also improved our financial profile |
| And then lastly, the diagnostics business is and has been stable, and we expect that to continue with patient volumes being quite strong and certainly at pre-pandemic levels |
| You can imagine, as we saw inflation pick up, there was a great deal to do, certainly in terms of driving price, which we did very well and well above our historical averages, but also to ensure that we maintained and improved on productivity |
| And we do see benefits of that as customers view us as the one player out there that can look across the entire manufacturing game plan and try to improve manufacturing yields, which offer so much more opportunity in terms of improvement for the industry |
| The belief is that the second half of '24 will be better than the first half |
| And then the math of the comps and the fact that our end markets continue to be quite robust, really plays out and leads us to believe that we'll have a small contraction, low single digits for the year |
| But we do believe that long term, China represents an attractive market |
| And then, of course, as we go forward in the second half, there's still that robust demand that I talked about with the end market, and that should then provide for those that we've talked about which is mid-single digits for the second half in bioprocessing, but an exit rate of high single digits or better as we go into 2025 |
| But I believe that the strength of our portfolio, the processes, the cost work that we've done will all play out as this -- you'll see all that play out as the normalization process plays out |
| We believe that we're well over an incremental $1 billion, $1.2 billion that is sustainable here for the long term |
| But independent of that, our view on China continues to be a positive one for the following factors |
| In fact, we just believe that it will continue in its strong growth as we go forward |
| And individual players will outperform or underperform that gravitational force, if you will, through innovation, through launching new solutions to customers that are oftentimes certainly in the early period after launch, a tailwind to growth |
| Then you have well over $1 billion non-respiratory business, which has been growing well over 20% here in the last year |
| We believe that our portfolio is perfectly positioned in order to support those efforts |
| I think more importantly is the fact that we have the broadest portfolio with all of the necessary product lines included |
| And just recently launched some really very strong innovations |
| We recently launched women's sexual health test that is also starting to gain traction on what is, by far, the largest menu |
| And so our team is uniquely driving that value proposition for share gain on top of what we're seeing here in terms of the organic growth rate of the market |
| Like just give us some more flavor underneath it exactly why the growth is so high at Cepheid? Rainer Blair So we have increased the installed base to well over 50,000 instruments here during the pandemic, and we continue to place instruments at a brisk pace, and that's related to the fact that this is just a fantastic solution at the point of care where doctors are making decisions -- therapeutic decisions |
| So I think that's incredibly important |
| Statement |
|---|
| 2023 was a challenging year for Danaher broadly for the industry |
| So we continue to believe per our guide that the first half will be soft as inventories continue to deplete |
| Your guidance is down low single digits |
| But just can you separate bioproduction in China and ex-China and what the guide incorporates? Rainer Blair So we would see bioprocessing in China being down mid- to high teens, which implies for the remainder of the global markets, flat to, let's say, low single-digit contraction |
| That continues, we believe, sort of with a declining trend here for the first half of this year |
| So maybe on '24, it guides low single-digit decline for core organic |
| We might have said in prior years that that's unlikely to pass, but in the current environment, we're unsure how that might play out |
| Dan Brennan As a reminder, you took over CEO of Danaher back September 2020, in the middle of COVID, quite a volatile period |
| The financial models need to show a return |
| You talked about, I think, life science and biotech decline, while diagnostics going to be growing |
| Dan Brennan And how do we think about China versus ex-China? Are there dramatically different assumptions? China has obviously been a steep decline, which you guys called out a quarter or 2 ago |
| And in China, we've said we don't expect an improvement in 2024 |
| We've paused those for our customers |
| Some players are perhaps not as strong as that's in one region versus the other |
Please consider a small donation if you think this website provides you with relevant information